Sangamo Therapeutics, Inc. (NASDAQ: SGMO) and Pfizer, Inc. (NYSE: PFE) today announced interim data from the Phase 1/2 Alta ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Management Comments

Sangamo Therapeutics (SGMO) Prices 11M Share Common Offering at $11.50/ShApril 4, 2019 8:03 AM Sangamo Therapeutics (SGMO) Continues to Gain, Now Up 50%April 2, 2019 8:39 AM Sangamo Therapeutics (SGMO) Hits Pre-Market High, Up 26%April 2, 2019 8:09 AM Sangamo and Pfizer Announce Phase 1/2 Interim Data For Investigational Hemophilia A Gene TherapyApril 2, 2019 7:00 AM Sangamo Therapeutics (SGMO) to Host April 2 Conference Call To Provide Clinical UpdateApril 1, 2019 5:23 PM Sangamo Therapeutics (SGMO) Highlights New Preclinical Data Demonstrating Significant Reduction in Tau Expression with Gene Regulation TechnologyMarch 29, 2019 7:02 AM